Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: Expert Opinions on HIV Cure Research
  
  • Email Email
  • Glossary Glossary
The Body Covers: The XIII International AIDS Conference
Safety and Efficacy of Abacavir and Efavirenz

July 11, 2000

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

  • PROTRA study: To evaluate the safety and efficacy of abacavir (ABC) and efavirenz (EFV) when substituted for a PI in HIV-1-infected subjects treated with two NRTIs and a PI with plasma HIV-RNA levels below the limit of assay quantification (Poster, TuPeB3210)
    Authored by M. Bickel, V. Rickerts, S. Klauke, J. Gould, J. Goldbach, V. Miller, S. Staszewski


Twenty-nine patients with good suppression of viral replication (viral loads less than 400 for at least three months and less than 50 at study entry) entered a pilot study ("PROTRA") that replaced their protease inhibitor (PI) with abacavir and efavirenz, and were followed for 48 weeks. On day one abacavir was added to the patients' currently successful combination of one PI and two NRTIs. At week six efavirenz was added and the PI was stopped. The two original NRTIs were continued. Almost equal numbers of patients had previously taken AZT/3TC and d4T/3TC as the nucleoside part of their regimen, and the majority (22) had taken indinavir as the PI. Measurement of serum lipids was done at specified intervals, and no significant changes were seen. This study is ongoing, but so far 16/16 patients that have reached week 48 have viral loads below 50 copies. Only one patient has been lost to follow up so far. In this uncontrolled pilot study, the PI that anchored a successful regimen was replaced by the most potent NRTI and NNRTI without any loss of viral control, but no advantageous changes in lipid profiles have been observed.

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

See Also
More on HIV Medications
Efavirenz (Sustiva, Stocrin)



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by The Body PRO. Copyright © Body Health Resources Corporation. All rights reserved.


Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

Advertisement